

# ACT:

## Artemisinin-based combination therapy



### Fighting malaria with ACTs

The World Health Organization recommends the use of artemisinin-based combination therapies. These medicinal treatments have proven especially effective against malaria infection as well as against the development of drug resistance by the malaria parasite, which currently occurs in particular with chloroquine and sulfadoxine-pyrimethamine antimalarial medicines.

### The advantage of blister packaging

IDA Foundation offers various quality-assured products in blister packaging with not-for-profit pricing. Blister packaging is extra convenient, hygienic and userfriendly, thus facilitating correct and successful treatment of patients.

### Artesunate and Amodiaquine combination therapies

IDA Foundation offers quality-assured Artesunate and Amodiaquine combination therapies in blister packaging for three patient groups: adults, children and infants. The specific dosage form is distinguished per patient group by colour.

Each blister package includes a specification leaflet with precautions and instructions for usage in four languages: English, French, Spanish and Portuguese. Product specification leaflets in these four languages are also included in each blister carton.



IDA Foundation  
Slochterweg 35  
1027 AA Amsterdam  
P.O. Box 37098  
1030 AB Amsterdam  
The Netherlands

Service Desk  
phone: +31 20 4033051  
fax: +31 20 4031854  
e-mail: [info@idafoundation.org](mailto:info@idafoundation.org)  
[www.idafoundation.org](http://www.idafoundation.org)

#### Adults

One adult malaria treatment / Un traitement paludisme adulte  
Un tratamiento malaria adulto / Um tratamento malaria adulto

White tablet / Comprimé blanc / Comprimido blanco / Comprimido branco  
Artesunate 50 mg / Artesunato 50 mg

Yellow tablet / Comprimé jaune / Comprimido amarelo / Comprimido amarelo  
Amodiaquine HCl 200 mg / Amodiaquina HCl 200 mg (eq 153 mg base)

Manufactured by: IDA Foundation, The Netherlands

Quality assurance and distribution by: IDA Foundation, The Netherlands

Day 1 / Jour 1 / Día 1 / Dia 1	Day 2 / Jour 2 / Día 2 / Dia 2	Day 3 / Jour 3 / Día 3 / Dia 3
4X (1 white + 1 yellow)	4X (1 white + 1 yellow)	4X (1 white + 1 yellow)

#### Children 6+

Malaria treatment for children over 6 years / Un traitement paludisme enfants de plus de 6 ans  
Un tratamiento malaria niños mayores de 6 años / Um tratamento malaria crianças acima de 6 anos

White tablet / Comprimé blanc / Comprimido blanco / Comprimido branco  
Artesunate 50 mg / Artesunato 50 mg

Yellow tablet / Comprimé jaune / Comprimido amarelo / Comprimido amarelo  
Amodiaquine HCl 200 mg / Amodiaquina HCl 200 mg (eq 153 mg base)

Manufactured by: IDA Foundation, The Netherlands

Quality assurance and distribution by: IDA Foundation, The Netherlands

Day 1 / Jour 1 / Día 1 / Dia 1	Day 2 / Jour 2 / Día 2 / Dia 2	Day 3 / Jour 3 / Día 3 / Dia 3
2X (1 white + 1 yellow)	2X (1 white + 1 yellow)	2X (1 white + 1 yellow)

#### Children 0-6

White tablet / Comprimé blanc / Comprimido blanco / Comprimido branco  
Artesunate 50 mg / Artesunato 50 mg

Yellow tablet / Comprimé jaune / Comprimido amarelo / Comprimido amarelo  
Amodiaquine HCl 200 mg / Amodiaquina HCl 200 mg (eq 153 mg base)

Manufactured by: IDA Foundation, The Netherlands

Quality assurance and distribution by: IDA Foundation, The Netherlands

	Day 1 / Jour 1 / Día 1 / Dia 1	Day 2 / Jour 2 / Día 2 / Dia 2	Day 3 / Jour 3 / Día 3 / Dia 3
1-6 years:	1X (1 white + 1 yellow)	1X (1 white + 1 yellow)	1X (1 white + 1 yellow)
0-1 years:	1X (1 white + 1 yellow)	1X (1 white + 1 yellow)	1X (1 white + 1 yellow)

### IDA Foundation

IDA Foundation is committed to improving access to and delivering high-quality essential medicines and medical supplies at the lowest cost to low- and medium-income countries. IDA Foundation is a partner of Roll Back Malaria (RBM).

- Quality Assurance: extensive quality assurance and control monitoring.
- Affordability: not-for-profit pricing & low-cost pricing agreements.
- Availability: over 700 products in stock, ready for immediate shipment
- Customer Service: swift deliveries; track&trace facility; product registration; assistance with legalities and funding requirements; close customer contact.

# Artesunate 50 mg + Amodiaquine HCl 200 mg

## TABLETS

### Artesunate and Amodiaquine HCl tablets

Each blister contains:

A: Amodiaquine HCl tablets. Each film-coated tablet contains 200 mg amodiaquine HCl equivalent to 153 mg amodiaquine.

B: Artesunate tablets. Each uncoated tablet contains 50 mg artesunate.

### Uses

Both amodiaquine and artesunate are effective in the treatment of uncomplicated *Plasmodium falciparum* malaria. It is recommended to use amodiaquine in combination with artesunate as the combination is more effective; recrudescence is prevented and is likely to decrease the emergence of drug resistance.

### Dosage

Dosage: amodiaquine 10 mg/kg/day and artesunate 4mg/kg/day both for 3 days.

Adults : 4 amodiaquine tablets + 4 artesunate tablets daily for 3 days.

Children over 6 years : 2 amodiaquine tablets + 2 artesunate tablets daily for 3 days.

Children 1-6 years : 1 amodiaquine tablet + 1 artesunate tablet daily for 3 days.

Children under 1 year : ½ amodiaquine tablet + ½ artesunate tablet daily for 3 days.

Doses may be taken with meals to lessen gastric upset.

### Pregnancy and breastfeeding

Use of artesunate is not recommended during the first trimester of pregnancy, except in case the benefits outweigh the risks, as seen in complicated or cerebral malaria. Amodiaquine should be used during pregnancy only if the benefits of therapy in pregnant women exposed to malaria outweigh the potential risks of the drug to the foetus. Artesunate is not known to cross into maternal milk. Chloroquine does not appear to be excreted in appreciable amounts in the breast milk. Because of amodiaquine's similarity with chloroquine, the same effects could be expected for pregnancy and breast feeding.

### Contra-indications and warnings

Artesunate should not be used in patients allergic to artesunate or to other artemisinin derivatives. It should be used with caution in patients with a history of liver disease, neurological disorders and cardiovascular disease. Since amodiaquine is known to concentrate in the liver, it should be used with caution in patients with hepatic disease or alcoholism and in patients receiving hepatotoxic drugs. If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuing the use of amodiaquine should be considered. Amodiaquine should be administered with caution to patients having glucose-6-phosphate dehydrogenase deficiency.

### Side effects

Abdominal cramps, mild diarrhoea, vomiting, headache, bradycardia, have been reported at elevated doses of artesunate. Oral administration of a single dose of amodiaquine may be followed by abdominal discomfort, mild diarrhoea, nausea, vomiting, headache, dizziness, blurring of vision, mental and physical weakness, fatigue. These symptoms are usually mild and transient. More severe adverse reactions include itching, cardiovascular abnormalities, dyskinesia, ocular damage, neuromuscular disorders and hearing loss. When given for prolonged period amodiaquine sometimes causes corneal deposits and a bluish grey pigmentation of the finger nails, skin and hard palate. Hepatitis and peripheral neuropathy have also been reported during use of amodiaquine.

### Overdosage

Symptoms:

Artesunate: In general, several times the treatment dose of artesunate does not cause adverse effects.

Amodiaquine: Headache, drowsiness, visual disturbances, vomiting, hypokalaemia, vascular collapse and cardiac and respiratory arrest.

Treatment: Treatment is symptomatic and must be prompt with immediate evacuation of the stomach by emesis or gastric lavage until the stomach is completely emptied.

### Storage

Store in a dry place below 25°C.